TECH:NASDAQBio-Techne Corp Analysis

Bio‑Techne (TECH) is trading in a tight range just below its 52‑week high, with the 20‑day SMA (71.6) comfortably above the 50‑day SMA (62.3) and 200‑day SMA (59.6), signaling a bullish trend. However, the RSI sits in the high‑70s, indicating overbought conditions, and the MACD histogram has turned negative, suggesting short‑term momentum may be weakening. The stock’s current price (~$72) is far above the DCF‑derived fair value of roughly $24, resulting in a substantial valuation gap and an upside/downside estimate of –3.3%. Despite a modest dividend yield of 0.44% and a payout ratio under 50%, the company’s high P/E (≈103) and forward P/E (≈35) reflect premium pricing relative to industry averages. Recent product launches in AI‑engineered designer proteins could fuel future growth, but a class‑action investigation surrounding a proposed Merck KGaA transaction adds legal uncertainty.
Overall, the technical picture is mixed—bullish trend but overbought momentum—while fundamentals point to significant overvaluation and elevated volatility. Investors should weigh the near‑term upside potential against the valuation disconnect and pending legal scrutiny.